Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Total Liabilities : $37.29 Mil (As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Total Liabilities?

Parnell Pharmaceuticals Holdings's Total Liabilities for the quarter that ended in Dec. 2018 was $37.29 Mil.

Parnell Pharmaceuticals Holdings's quarterly Total Liabilities increased from Dec. 2016 ($29.03 Mil) to Dec. 2017 ($31.74 Mil) and increased from Dec. 2017 ($31.74 Mil) to Dec. 2018 ($37.29 Mil).

Parnell Pharmaceuticals Holdings's annual Total Liabilities increased from Dec. 2016 ($29.03 Mil) to Dec. 2017 ($31.74 Mil) and increased from Dec. 2017 ($31.74 Mil) to Dec. 2018 ($37.29 Mil).

Parnell Pharmaceuticals Holdings Total Liabilities Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Total Liabilities Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

Total Liabilities

Get a 7-Day Free Trial

10.27

18.81

29.03

31.74

37.29

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
Total Liabilities	Get a 7-Day Free Trial			10.27	18.81	29.03	31.74	37.29

Parnell Pharmaceuticals Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Parnell Pharmaceuticals Holdings's Total Liabilities for the fiscal year that ended in Dec. 2018 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.849	+	(32.282	+	0.00099999999999636
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.044	+	0.109)
	=	37.29

Total Liabilities	=	Total Assets (A: Dec. 2018 )	-	Total Equity (A: Dec. 2018 )
	=	24.003	-	-13.282
	=	37.29

Parnell Pharmaceuticals Holdings's Total Liabilities for the quarter that ended in Dec. 2018 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.849	+	(32.282	+	0.00099999999999636
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.044	+	0.109)
	=	37.29

Total Liabilities	=	Total Assets (Q: Dec. 2018 )	-	Total Equity (Q: Dec. 2018 )
	=	24.003	-	-13.282
	=	37.29

Parnell Pharmaceuticals Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.